TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.

ABSTRACT: The resurgence of immunotherapy as an effective anticancer strategy has been coupled with more mature understandings of the underlying immune pathways and the development of novel immune checkpoint targets. The clinical development of antibodies first directed against cytotoxic T-lymphocyte-associated antigen 4, and later against program death 1, achieved durable disease control in a subset of patients across a large number of tumor types. Previous work demonstrates that targeting the programmed death 1 pathway alone does not result in complete restoration of T cell function and in some cancers, targeting this axis does not restore T cell function at all, suggesting a need to identify other molecules and inhibitory pathways that are involved in T cell exhaustion. In a comprehensive immune

SUBMITTER: Attalla K 

PROVIDER: S-EPMC7980780 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature